Precision Biosciences INC Form 4 insider transactions

Director Melinda Brown was granted 20,979 restricted stock units by Precision BioSciences, Inc.

Precision BioSciences director Stanley Frankel was granted 20,979 restricted stock units as part of standard equity compensation.

Director Geno J. Germano was granted 20,979 restricted stock units as part of the company's equity compensation program.

Director Shari Lisa Pire was granted 20,979 restricted stock units by Precision BioSciences, Inc.

Precision BioSciences director Kevin Buehler was granted 20,979 restricted stock units as part of standard equity compensation.

Precision BioSciences reports the grant of 57,389 restricted stock units to Chief Research Officer J. Jefferson Smith.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences Inc., received an award of 107,604 restricted stock units.

Michael Amoroso, President and CEO of Precision BioSciences, has been granted 573,888 restricted stock units, vesting over three years.

Director Kevin Buehler acquired 21,000 shares of Precision BioSciences common stock following the vesting of restricted stock units.

Precision BioSciences director Stanley Frankel acquired 21,000 shares of common stock following the vesting of restricted stock units.

Director Melinda Brown acquired 21,000 shares of Precision BioSciences common stock through the vesting of restricted stock units.

Director Shari Lisa Pire acquired 21,000 shares of Precision BioSciences common stock following the vesting of restricted stock units.

Director Geno J. Germano acquired 21,000 shares of Precision BioSciences common stock through the vesting of restricted stock units.

Precision BioSciences CEO Michael Amoroso sold 20,559 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Precision Biosciences CFO John Alexander Kelly reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Precision BioSciences' General Counsel, Dario Scimeca, sold 4,925 shares of common stock to cover tax obligations following the vesting of 16,667 Restricted Stock Units.

Precision BioSciences' Chief Research Officer, J. Jefferson Smith, reported the vesting of Restricted Stock Units and a subsequent sell-to-cover transaction for tax obligations.

Precision BioSciences CEO Michael Amoroso reported the vesting of Restricted Stock Units and a subsequent sell-to-cover transaction for tax obligations.

Precision BioSciences' General Counsel, Dario Scimeca, reported a routine 'sell-to-cover' transaction following RSU vesting.

Precision Biosciences CFO John Alexander Kelly reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Precision BioSciences' Chief Research Officer, J. Jefferson Smith, reported the vesting of restricted stock units and a subsequent sell-to-cover transaction for tax obligations.

A director at Precision BioSciences, Geno J Germano, has purchased 3,000 shares of common stock, increasing his beneficial ownership.

Precision Biosciences Director Stanley Frankel filed a Form 4 reporting a planned acquisition of 2,700 shares of common stock at $4.70 per share under a Rule 10b5-1 plan.

Melinda Brown, a Director at Precision BioSciences Inc., acquired 1,381 shares of common stock at a weighted average price of $4.97 per share.

Precision BioSciences Chief Financial Officer John Alexander Kelly reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Precision BioSciences General Counsel Dario Scimeca sold 665 shares of common stock for tax purposes following the vesting of 1,835 Restricted Stock Units.

Precision BioSciences CEO Michael Amoroso sold shares to cover tax obligations following the vesting of Restricted Stock Units.

Precision BioSciences Inc. Director Stanley Frankel acquired 2,700 shares of common stock at $4.97 per share.

Precision BioSciences Director Melinda Brown purchased 1,400 shares of common stock, increasing her beneficial ownership.

Precision Biosciences' Chief Financial Officer, John Alexander Kelly, sold 14,827 shares of common stock at $4.26 per share on July 3, 2025, solely to cover tax withholding obligations related to the vesting of restricted stock units.